Managed Access Programs for INC424, Ruxolitinib

ConditionsPrimary Myelofibrosis (PMF)Post Polycythemia Myelofibrosis (PPV MF)Thrombocythemia Myelofibrosis (PET-MF)Severe/Very Severe COVID-19 Illness Polycythemia Vera (PV)Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD)Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)

Trial statusAvailable

Trial phaseNot listed

Trial typeExpanded Access

Biological sexAll

Age2+

SponsorNovartis Pharmaceuticals

About this trial

The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib

Eligibility criteria

Qualifiers

An independent request was received from a licensed physician.

The patient has a serious or life-threatening disease or condition and there is no comparable or satisfactory alternative therapy available for diagnosis, monitoring, or treatment.

The patient is not eligible or able to enroll in a clinical trial or continue participation in such trial.

There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.

Disqualifiers

None

Trial design

Treatments tested in this trial

Ruxolitinib

Treatment groups

No treatment groups listed

Locations

This trial has no locations

Sponsors and collaborators

Novartis Pharmaceuticals

Lead sponsor

Source ClinicalTrials.gov